Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $31,176.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 1,299 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $24.00, for a total value of $31,176.00. Following the completion of the sale, the insider directly owned 399,989 shares of the company’s stock, valued at approximately $9,599,736. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.00, for a total transaction of $10,714.00.
• On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00.
• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00.

Adaptive Biotechnologies Stock Performance

Shares of ADPT stock opened at $24.60 on Thursday. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The business has a 50 day moving average of $20.04 and a two-hundred day moving average of $16.78. Adaptive Biotechnologies Corporation has a 52 week low of $10.65 and a 52 week high of $24.96. The company has a market cap of $3.94 billion, a P/E ratio of -60.00 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The company had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.17) earnings per share. As a group, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.41 EPS for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at $28,000. EverSource Wealth Advisors LLC grew its holdings in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares during the period. KBC Group NV acquired a new position in Adaptive Biotechnologies during the first quarter worth about $45,000. Assetmark Inc. grew its holdings in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after acquiring an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies in the fourth quarter worth about $51,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ADPT shares. Morgan Stanley increased their target price on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. TD Cowen boosted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. JPMorgan Chase & Co. dropped their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Piper Sandler lifted their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday. Finally, BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus target price of $24.42.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.